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CLINICAL SNIPPETS
Halting Progression
In an effort to more carefully 
define the mechanism of 
melanoma progression, Lupia 
and colleagues examined 
the effects of silencing 
and overexpression of the 
tetraspannin CD63 on the 
epithelial-to-mesenchyme 
transition (EMT), which is 
thought to represent the 
progression of melanoma 
lesions via changes in invasive, 
stemness, and metastatic 
characteristics. Using melanoma 
cell lines, a mouse xenograft 
tumor model, and human 
melanoma biopsies, the 
investigators demonstrated 
that CD63 is a potent negative 
regulator of EMT in melanoma 
cells, as CD63 silencing resulted 
in an aggressive phenotype 
whereas overexpression 
resulted in reduced cell motility, 
invasiveness, and tumorigenicity. 
See page 2947
Bad Hair Days
Hair loss attributable to massive 
apoptosis of hair matrix 
keratinocytes is common 
following chemotherapy; 
however, no effective treatment 
to prevent or slow this effect is 
available, partly owing to our 
lack of understanding of the 
underlying mechanism. In an ex 
vivo model of chemotherapy-
induced hair loss, Sharova and 
colleagues demonstrated that 
early hair follicle response to 
the widely used anticancer 
drug doxorubicin involves 
upregulation of apoptosis-
related genes as well as dramatic 
reorganization of the terminal 
differentiation programs of the 
keratinocytes, perhaps paving 
the way for development of 
drug-specific hair-protective 
options for cancer patients.  
See page 2873 
Two-for-One Special
Following 8 months of treatment with the Janus 
kinase inhibitor tofacitinib citrate, which has 
been approved for treatment of rheumatoid 
arthritis, a 25-year-old patient with plaque 
psoriasis and concomitant alopecia univer-
salis (AU) experienced total regrowth of hair 
at all body sites, and the remaining psoriasis 
was no longer bothersome to the patient. 
Tofacitinib affects T lymphocytes and thus, not 
surprisingly, mediates inflammatory diseases. 
Craiglow and King report the first use of effec-
tive pathogenesis-based therapy for AU and, 
more importantly, heralds the positive effects of a single agent for two seemingly 
disparate diseases with distinct pathomechanisms. See page 2988 
The Loop Goes On
The common autoimmune blistering skin 
disease bullous pemphigoid (BP) involves 
autoantibody binding; however, additional 
inflammatory mechanisms are essential for 
subepidermal blister formation. Le Jan and col-
leagues demonstrated that, despite the high 
IL-17 levels in the blister fluids of BP patients, 
the IL-17-induced inflammatory response was 
controlled by innate immune cells, including 
neutrophils but not T helper type 17 cells. 
A resultant autoamplification loop, which 
involves upregulation of detrimental prote-
ases by IL-17, may self-reinforce the chronic 
inflammation and lead to tissue damage in BP 
patients with severe disease. These findings support additional clinical investigations 
into modulation of the IL-17 pathway for treatment of bullous autoimmune diseases. 
See page 2908 
Algorithm for Diagnosis
Following a genome-wide methylation screen, 
Gao and colleagues studied promoter CpG 
island methylation of selected genes in search 
of diagnostic markers to facilitate discrimina-
tion of melanoma from dysplastic nevi, which 
is considered an intermediate stage between 
common nevus and melanoma. Progressive 
CpG island methylation was revealed, with the 
lowest levels in common nevi and increasing 
levels in dysplastic nevi, melanoma, and, final-
ly, metastatic disease. These investigators proposed a diagnostic algorithm to distin-
guish melanoma from benign lesions. Methylation of CLDN11, CDH11, PP1R3C, 
and GNMT may indicate malignancy, suggesting that examination of these factors 
may aid in the difficult molecular diagnosis of melanocytic lesions. See page 2957
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